Scarica l'app Stockscreener
0.749
3.97%
-0.031
Pre-mercato:
.76
0.011
+1.47%
Precedente Chiudi:
$0.78
Aprire:
$0.81
Volume 24 ore:
3.08M
Relative Volume:
2.33
Capitalizzazione di mercato:
$1.46M
Reddito:
-
Utile/perdita netta:
$-19.39M
Rapporto P/E:
-0.0396
EPS:
-18.9115
Flusso di cassa netto:
$-15.34M
1 W Prestazione:
+1.93%
1M Prestazione:
-31.28%
6M Prestazione:
-88.74%
1 anno Prestazione:
+436.92%
Intervallo 1D:
$0.7213
$1.04
Intervallo di 1 settimana:
$0.69
$1.04
Portata 52W:
$0.0927
$15.90
Glucotrack Inc Stock (GCTK) Company Profile
Nome
Glucotrack Inc
Settore
Industria
Telefono
972 (8) 675-7878
Indirizzo
301 RT 17 NORTH, RUTHERFORD
Compare GCTK vs ISRG, BDX, MDLN, ALC, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.749 | 1.46M | 0 | -19.39M | -15.34M | -18.91 |
ISRG
Intuitive Surgical Inc
|
451.29 | 160.28B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.69 | 44.57B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
47.51 | 38.56B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
77.82 | 37.93B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
221.22 | 32.23B | 5.40B | 1.49B | 1.78B | 10.12 |
Glucotrack Inc Borsa (GCTK) Ultime notizie
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant - Yahoo Finance
Glucotrack publishes peer-reviewed study on glucose sensor stability - Investing.com
Glucotrack publishes peer-reviewed study on glucose sensor stability By Investing.com - Investing.com Canada
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology - marketscreener.com
One-year lab test backs Glucotrack implantable glucose monitor - Stock Titan
GCTK | GlucoTrack, Inc. Common Stock Insider Trading - Quiver Quantitative
GlucoTrack Executes Debt-for-Equity Exchange to Reduce Obligations - TipRanks
Glucotrack exchanges $600,000 note for 895,000 shares with investor By Investing.com - Investing.com
Glucotrack Swaps $600,000 Note Portion for 895,000 Shares Under Exchange Agreement - TradingView
Glucotrack (NASDAQ: GCTK) swaps $600K debt for 895,000 shares - Stock Titan
GlucoTrack stock gains as data backs FDA filing plans for glucose monitoring tech - MSN
Technical Analysis: Is GlucoTrack Inc impacted by rising ratesProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
$Glucotrack (GCTK.US)$ thanks market - Moomoo
RSI Check: Will GlucoTrack Inc benefit from geopolitical trends2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
Glucotrack reports net loss of USD 19.4M in FY 2025 - Medical Buyer
Glucotrack, Inc. 2025 Annual Report – Implantable Continuous Blood Glucose Monitor Development, Regulatory Progress, and Risk Factors 66 - Minichart
Glucotrack FY25 Net Loss Narrows; Plans To Submit An IDE For CBGM In Q2 2026 - RTTNews
GCTK: Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM - TradingView — Track All Markets
Glucotrack (GCTK) advances implantable CBGM but flags going concern risk - Stock Titan
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials - Stock Titan
Glucotrack, Inc. Announces IDE Filing Plans for Continuous Blood Glucose Monitoring Technology and Patents Issued by USPTO - Quiver Quantitative
Glucotrack’s 3-year glucose implant targets a U.S. human trial in 2026 - Stock Titan
GCTK stock is soaring pre-market today — what is fueling the surge? - MSN
Technical Analysis: What analysts say about GlucoTrack Inc stock2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
GlucoTrack Plummets 27%: Is This the Bottom of a Deep Downtrend? A High-Stakes Analysis for 2026 - Bitget
GCTK PE Ratio & Valuation, Is GCTK Overvalued - Intellectia AI
GlucoTrack Prepares FDA Submission for Implantable CBGM Trial - The Globe and Mail
Glucotrack plans FDA submission for implantable glucose monitor By Investing.com - Investing.com Australia
Glucotrack to File for FDA Exemption Based on 2025 Milestones - Yahoo Finance
GCTK Stock Is Soaring Today — What Is Fueling The Surge? - Stocktwits
Glucotrack to Submit IDE Application to FDA in Early Q2 - citybiz
Glucotrack, Inc. (GCTK) Stock: Prepares FDA Submission as Clinical Data Shows Strong Accuracy - parameter.io
Glucotrack plans US trial of implantable glucose monitor this year - MedTech Dive
Microcap MedTech Moving on U.S. Clinical Milestone - The Globe and Mail
GCTK stock GlucoTrack NASDAQ +29.80% on FDA IDE plan 27 Mar 2026: Earnings in focus - Meyka
Latest Developments Propel GCTK Stock with Breakthrough Acquisitions - StocksToTrade
Why Is GlucoTrack Stock Soaring Friday?GlucoTrack (NASDAQ:GCTK) - Benzinga
GlucoTrack (GCTK) Surges 45% in Afternoon Trading—What's Fueling This Unusual Move? - Bitget
Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones - marketscreener.com
Glucotrack plans FDA submission for implantable glucose monitor - investing.com
Glucotrack to file IDE with FDA in Q2 2026 after successful human trials and new patents - TradingView
GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge? - Stocktwits
Glucotrack (NASDAQ: GCTK) advances implantable CBGM with IDE plan and new patents - Stock Titan
Glucotrack to file significant IDE with FDA for US clinical trial in early Q2 based on critical 2025 milestones - MarketScreener
Glucotrack Plans IDE Submission to FDA in Early Q2 2026 for Non-Invasive Glucose Monitoring Clinical Trials - geneonline.com
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones - marketscreener.com
Is GlucoTrack Inc. a stock for growth or value investorsWeekly Market Outlook & Weekly Top Stock Performers List - baoquankhu1.vn
Sentiment Review: What analysts say about GlucoTrack Inc stockOptions Play & Precise Entry and Exit Recommendations - baoquankhu1.vn
Growth Recap: Is GlucoTrack Inc backed by strong institutional buying2026 Closing Moves & Short-Term High Return Ideas - baoquankhu1.vn
Glucotrack Inc Azioni (GCTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.86%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):